121 stories from 17 sources
The week in Medicine and Healthcare
Click on a headline to see stories that shaped it.
Threads
8 threads
Pennsylvania's measles toll rose from three deaths to four as the state sought CDC assistance, while national deaths and disputes over vaccine policy intensified. Kennedy's renewed alignment with anti-vaccine activism added political pressure as officials tried to close immunization gaps.
Medicare's AI prior-authorization pilot exposed high denial rates, delayed care, and weak accountability. As the FDA preserved premarket review for radiology AI and struggled with staffing, broader healthcare AI efforts faced growing demands for evidence and scrutiny.
The obesity-drug contest moved beyond scientific leadership toward manufacturing, pricing, supply, and organizational execution. Companies are also pushing into younger patients as demand and competition expand.
The Democratic Republic of the Congo saw uneven Ebola progress and rising cases in North Kivu, then paired frontline vaccination with a large clinical trial. The combined approach seeks immediate protection while building evidence for future outbreaks.
Drugmakers increasingly licensed promising medicines from Chinese biotech firms, including a major multiple myeloma deal. The week framed China as both an innovation source and a target for global pharmaceutical partnerships.
Fiji declared a national HIV emergency after infections surged, with drug use contributing to transmission and prevalence reaching an estimated one in 60 adults. The response now requires rapid expansion of testing, treatment, prevention, and support.
A Justice Department settlement required NYU Langone to pay $8.5 million and stop providing gender-affirming care to minors. The agreement shows how federal enforcement can restrict care even where state law permits it.
Moderna and Merck's personalized cancer vaccine met its primary endpoint in a Phase 3 melanoma trial, moving individualized treatment closer to regulatory review. Production speed and cost remain central to whether the approach can reach patients broadly.
Day’s Recap